Holen Sie sich die Stockscreener-App
14.93
0.53%
-0.08
Handel nachbörslich:
14.75
-0.18
-1.21%
Schlusskurs vom Vortag:
$15.01
Offen:
$14.86
24-Stunden-Volumen:
66,259
Relative Volume:
0.65
Marktkapitalisierung:
$308.79M
Einnahmen:
$306.91M
Nettoeinkommen (Verlust:
$-59.11M
KGV:
-99.53
EPS:
-0.15
Netto-Cashflow:
$6.35M
1W Leistung:
+1.05%
1M Leistung:
-4.60%
6M Leistung:
+80.40%
1J Leistung:
+24.42%
1-Tages-Spanne:
$14.73
$15.00
1-Wochen-Bereich:
$14.63
$15.46
52-Wochen-Spanne:
$7.08
$17.49
Amarin Corp Adr Stock (AMRN) Company Profile
Firmenname
Amarin Corp Adr
Sektor
Telefon
353 1 6699 020
Adresse
SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2
Vergleichen Sie AMRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRN
Amarin Corp Adr
|
14.93 | 310.45M | 306.91M | -59.11M | 6.35M | -0.15 |
|
LLY
Lilly Eli Co
|
748.19 | 677.17B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
177.40 | 428.83B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
217.61 | 385.71B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
123.31 | 240.28B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
81.02 | 206.84B | 63.43B | 16.42B | 14.72B | 6.49 |
Amarin Corp Adr Stock (AMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-10-25 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-06 | Hochstufung | Jefferies | Hold → Buy |
| 2022-05-06 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-05 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-05-05 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-05-04 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2021-05-12 | Herabstufung | Goldman | Neutral → Sell |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-05 | Eingeleitet | Northland Capital | Outperform |
| 2020-03-31 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-31 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-31 | Hochstufung | Oppenheimer | Underperform → Perform |
| 2020-03-13 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-02 | Eingeleitet | Cowen | Outperform |
| 2020-02-18 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-01-06 | Eingeleitet | JP Morgan | Neutral |
| 2019-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2019-11-20 | Eingeleitet | Oppenheimer | Underperform |
| 2019-11-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-11-15 | Bestätigt | SVB Leerink | Outperform |
| 2019-10-31 | Eingeleitet | Aegis Capital | Buy |
| 2019-10-15 | Eingeleitet | Goldman | Neutral |
| 2019-08-14 | Eingeleitet | SVB Leerink | Outperform |
| 2019-07-09 | Bestätigt | Jefferies | Buy |
| 2019-06-17 | Eingeleitet | ROTH Capital | Buy |
| 2019-03-22 | Eingeleitet | Stifel | Buy |
Alle ansehen
Amarin Corp Adr Aktie (AMRN) Neueste Nachrichten
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises - Barchart.com
Amarin Gears Up To Report Q2 Earnings: Here's What To Expect - Barchart.com
VKTX Stock Down On Wider-Than-Expected Loss In Q2, Nil Sales - Barchart.com
Zacks.com featured highlights include Mama's Creations, Bassett Furniture Industries and Amarin - Barchart.com
KRYS Begins Dosing With Gene Therapy In Rare Eye Disease, Stock Up - Barchart.com
RYTM Stock Rises On Upbeat Acquired Hypothalamic Obesity Study Data - Barchart.com
PROK Surges More Than 500% On Upbeat Data From Kidney Cell Therapy Study - Barchart.com
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU - Yahoo Finance
Amarin licenses VAZKEPA to Recordati in 59 European countries - Investing.com
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
KURA Stock Rises More Than 15% This Past Week: Here's Why - Barchart.com
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year? - Yahoo Finance
RCKT Stock Tanks On Patient Death In Danon Disease Study - Barchart.com
SpringWorks Gets CHMP Nod For Mirdametinib In Rare Disease - Barchart.com
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y - Barchart.com
Amarin earnings beat by $0.04, revenue topped estimates - Investing.com
Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 - Barchart.com
Press Release Distribution & PR Platform - ACCESS Newswire
Looking For A Top Momentum Stock? Check Out Amarin Corp ADR (NASDAQ: AMRN) - Stocksregister
Amarin Takes Critical Step to Avoid Nasdaq Delisting with 1-for-20 Share Consolidation - Stock Titan
Amarin announces ADS ratio change to meet Nasdaq requirements - Investing.com
Major Shake-up: Investment Firm Leader Joins Amarin Board to Drive Shareholder Value - Stock Titan
Amarin adds investment expert Michael Torok to Board By Investing.com - Investing.com
Upcoming Stock Splits This Week (April 7 to April 11) – Stay Invested - markets.businessinsider.com
A Look at New Gold Inc (NGD) Shares in the Recent Past Indicates Growth - Sete News
Breakthrough: EPA Treatment Shows Double Impact on Heart Disease When Combined with Popular Diabetes Drug - Stock Titan
Amarin announces board member departure ahead of annual meeting - Investing.com
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - TradingView
Amarin urged to review strategy by major shareholders - Investing.com
Amarin Corporation plc (NASDAQ:AMRN) Q4 2024 Earnings Call Transcript - Insider Monkey
Amarin Corp PLC (AMRN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Expanding ... - Yahoo Finance
Amarin announce splan to initiate ratio change under ADR program - TipRanks
Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program - The Manila Times
Amarin Corp. (AMRN) Announces 1-For-20 ADS Ratio Change to Maintain Nasdaq Listing - StreetInsider
Amarin Plans Major ADR Restructuring: What This 1:20 Ratio Change Means for Investors - StockTitan
Amarin Announces 1-for-20 Reverse Stock Split - TipRanks
How Amarin's Latest European Reimbursement Victory Strengthens Its Cardiovascular Market Position - Stock Titan
Will Amarin's Q4 Earnings Mark a Turning Point? Key Date and Details Revealed - Stock Titan
Amarin stock plunges to 52-week low of $0.46 amid challenges - Investing.com
Amarin granted extension to meet Nasdaq listing standards - Investing.com
Top 3 Health Care Stocks You'll Regret Missing In Q4Amarin Corp (NASDAQ:AMRN) - Benzinga
Amarin to present new cardiovascular research at ESC Congress - Investing.com
China approves VASCEPA to reduce cardiovascular risk - Investing.com
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - 富途牛牛
Amarin's VAZKEPA gains reimbursement approval in Greece - Investing.com
Amarin secures new patent for heart drug VAZKEPA in Europe - Investing.com
Why Pharma Company Amarin Shares Are Zooming Today - Markets Insider
GSK Gears Up to Report Q1 Earnings: What's in the Cards? - Nasdaq
Sarissa Capital Calls for Amarin Special Meeting to Vote on Its Nominees - 24/7 Wall St.
股神出手｜畢菲特首度買進台積電ADR 涉逾41.2億美元 4家避險基金均增持台積電 - Yahoo 財經
Finanzdaten der Amarin Corp Adr-Aktie (AMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):